archive-com.com » COM » E » ENDEAVOURVISION.COM

Total: 462

Choose link from "Titles, links and description words view":

Or switch to "Titles and links view".
  • Daniel Bertholet - Senior Investment Director
    consultant in country risk assessment for Business Environment Risk Intelligence BERI in the US and Switzerland Daniel is a member of the Medtech Task Force of the European Venture Capital Association EVCA and has spoken at numerous industry events in the US and Europe Daniel holds an MBA with honours from the Institut d Etudes Politiques in Paris and a MA in International Political Economy from the American University in Washington DC Daniel is personally committed to support vulnerable children in Sub Saharan Africa He lives in Geneva with his wife and their three children tel 41 22 544 6030 email vcard open vcard His favourite question to entrepreneurs What makes you passionate about your business Endeavour Vision SA 2006 2016 Terms Conditions The partners have been very supportive of our approach and stepped in to add value when needed I would strongly recommend them as investors Didier Cowling Founder and CEO Kuros Biosurgery AG In preparing for our dual IPOs on the Nasdaq and Neuer Markt it was very important for SCM Microsystems to gain insight and access to the European investment scene This team helped SCM build the foundation for our successful offerings not only with capital but with sound guidance and value added services as well Robert Schneider founder and CEO SCM Microsystems Inc VC is about funding your project but it is more about extending your core team Thus it is about partnering with those who are great to work with and are team players Those who understand your business and embrace your vision Those who know how to challenge your execution and to bring value This is why I recommend Endeavour Vision team to entrepreneurs looking for funding Dr Georges Karam co Founder President CEO Sequans With Endeavour Vision we have been able to establish

    Original URL path: http://www.endeavourvision.com/team-2-5-Sven+Lingjaerde.htm (2016-04-25)
    Open archived version from archive


  • CeQur Announces Publication Of Study Results On PaQ® Insulin Delivery Device To Reduce Barriers To Insulin Therapy
    potentially supporting improved adherence to insulin therapy he added Eighteen study participants used the PaQ device for two weeks and reported a strong and significant reduction in overall BIT difference 5 4 0 77 p 0 01 effect size 0 70 The majority of the patients perceived less stigmatization less hardship from insulin therapy and injection and less fear concerning hypoglycemia Negative attitudes toward treatment and patient distress were also slightly reduced It is possible that this reduction of insulin therapy barriers may have contributed to the trend toward improved glycemic control that was also observed in this study and previously reported in the journal Diabetes Care added Doug Lawrence CeQur s CEO in a press release The data published today demonstrate that PaQ does exactly what we envisioned it would do simplify insulin therapy to make it easier and more comfortable for people with type 2 diabetes to adhere to their treatment and we hope live healthier happier lives as a result concluded Lawrence back Endeavour Vision SA 2006 2016 Terms Conditions The partners have been very supportive of our approach and stepped in to add value when needed I would strongly recommend them as investors Didier Cowling Founder and CEO Kuros Biosurgery AG In preparing for our dual IPOs on the Nasdaq and Neuer Markt it was very important for SCM Microsystems to gain insight and access to the European investment scene This team helped SCM build the foundation for our successful offerings not only with capital but with sound guidance and value added services as well Robert Schneider founder and CEO SCM Microsystems Inc VC is about funding your project but it is more about extending your core team Thus it is about partnering with those who are great to work with and are team players Those

    Original URL path: http://www.endeavourvision.com/news-n255-c67-CeQur+Announces+Publication+Of+Study+Res.htm (2016-04-25)
    Open archived version from archive

  • CeQur Announces Publication of Data Demonstrating PaQ® Insulin Delivery Device Reduces Barriers to Insulin Therapy
    injection and less fear about hypoglycemia Negative attitudes toward insulin treatment and patients diabetes related distress were also slightly reduced It is possible that this reduction of insulin therapy barriers may have contributed to the trend toward improved glycemic control that was also observed in this study and previously reported in the journal Diabetes Care said Doug Lawrence CEO of CeQur Data from a questionnaire evaluating satisfaction with PaQ including time required to maintain the device administer an insulin dose and learn how to use the device revealed a high level of PaQ satisfaction and acceptance All but one device satisfaction and acceptance measure scored above 4 on a scale of 1 to 5 with 5 representing maximum satisfaction indicating high and very high satisfaction with PaQ The data published today demonstrate that PaQ does exactly what we envisioned it would do simplify insulin therapy to make it easier and more comfortable for people with type 2 diabetes to adhere to their treatment and we hope live healthier happier lives as a result said Lawrence The Need for Simple Insulin Infusion Every day more than 11 million people with type 2 diabetes in the United States and Europe inject insulin to manage their disease The majority of these people are not achieving target glycemic control Studies suggest that simple CSII regimens may improve glycemic control and quality of life among these individuals however current CSII has not been widely used in this population to date due to its complexity and cost About PaQ PaQ Insulin Delivery Device is a simple and cost effective three day insulin delivery device that enables patients to experience the benefits of CSII without the complexity of daily insulin injections PaQ provides three days of consistent basal insulin along with easy on demand bolus insulin PaQ can reduce known barriers to insulin therapy and has proven effective in clinical trials and usability studies PaQ has CE Mark approval and will address the emerging 3 billion market for simple insulin infusion About CeQur CeQur is dedicated to developing and commercializing advanced insulin delivery devices that make it easier for people living with type 2 diabetes to adhere to therapy and stay in control of their disease The company is headquartered in Horw Switzerland with operations in Nordborg Denmark and Marlborough Massachusetts CeQur was established in January 2008 The company s lead product candidate is the PaQ Insulin Delivery Device a three day wearable device that provides freedom from multiple daily injections More information can be found at www cequrcorp com back Endeavour Vision SA 2006 2016 Terms Conditions The partners have been very supportive of our approach and stepped in to add value when needed I would strongly recommend them as investors Didier Cowling Founder and CEO Kuros Biosurgery AG In preparing for our dual IPOs on the Nasdaq and Neuer Markt it was very important for SCM Microsystems to gain insight and access to the European investment scene This team helped SCM build the foundation for

    Original URL path: http://www.endeavourvision.com/news-n253-c67-CeQur+Announces+Publication+of+Data+Demo.htm (2016-04-25)
    Open archived version from archive

  • CeQur Appoints Douglas Lawrence Chief Executive Officer
    a range of functions including market analytics finance corporate strategy marketing commercial and R D before moving into several general management positions I was drawn to CeQur by the unprecedented opportunity to guide an exceptional team as they launch an innovative and simple technology that will dramatically alter the landscape of insulin treatment said Lawrence PaQ has demonstrated the ability to make a real difference for the millions of people around the world who are struggling every day to manage their disease As CEO Lawrence will lead the transition of CeQur from the pilot manufacturing stage through establishment of high volume manufacturing capacity regulatory approval in the United States and PaQ international commercialization Over the past six years we have created and validated a unique technology with the potential to significantly reduce the burden of daily insulin injections for the millions of people with type 2 diabetes said Peterson I am confident that Doug s capabilities and background make him the ideal leader to help our team optimize commercialization and position PaQ as the leader in simple insulin infusion About PaQ The lead product candidate from CeQur is the PaQ Insulin Delivery Device a simple and affordable device that enables patients to experience the benefits of continuous insulin infusion without the burden of daily insulin injections PaQ provides three days of consistent basal insulin along with easy on demand bolus insulin PaQ can reduce known barriers to insulin therapy and has proven effective in clinical trials and usability studies PaQ has CE Mark approval and will address the emerging 3 billion market for simple insulin infusion The Need for Simple Insulin Infusion There are currently more than 11 million people with type 2 diabetes T2D in the United States and the European Union who are taking daily insulin injections The majority of these people are not achieving target glycemic control Studies suggest that continuous subcutaneous insulin infusion CSII can improve glycemic control and quality of life However due to complexity and cost CSII is not widely used in T2D About CeQur SA CeQur is developing and commercializing advanced insulin delivery devices that make it easier for people living with type 2 diabetes to adhere to therapy and stay in control of their disease CeQur was established in January 2008 and is headquartered in Horw Switzerland with operations in Nordborg Denmark and Marlborough Massachusetts More information can be found at www cequrcorp com Contact Michele Parisi 925 429 1850 mparisi biocommnetwork com back Endeavour Vision SA 2006 2016 Terms Conditions The partners have been very supportive of our approach and stepped in to add value when needed I would strongly recommend them as investors Didier Cowling Founder and CEO Kuros Biosurgery AG In preparing for our dual IPOs on the Nasdaq and Neuer Markt it was very important for SCM Microsystems to gain insight and access to the European investment scene This team helped SCM build the foundation for our successful offerings not only with capital but with sound guidance and

    Original URL path: http://www.endeavourvision.com/news-n220-c67-CeQur+Appoints+Douglas+Lawrence+Chief+Ex.htm (2016-04-25)
    Open archived version from archive

  • Diabetes Care Publishes Data Demonstrating PaQ® Insulin Delivery Device Could Help People with Type 2 Diabetes Overcome Barriers to Insulin Adherence and Improve Clinical Outcomes
    an alternative to insulin injections but adoption has been limited by the complexity and cost of existing approved CSII devices PaQ is a simple CSII device with demonstrated ability to safely and effectively address many of the issues that make daily injection therapy a challenge for so many people with diabetes said James Peterson founder and CEO CeQur The data published today demonstrate PaQ has the potential to reduce the daily insulin injection burden and thereby to improve clinical outcomes for a growing number of people worldwide In the six week prospective study 19 participants transitioned from multiple daily injections to PaQ treatment all demonstrated competency in assembling placing and using the device following just one hour of training Changes in self monitored blood glucose values during PaQ therapy showed a trend toward better glycemic control compared to baseline at multiple points throughout the day Blinded continuous glucose monitoring CGM data during PaQ therapy also revealed a trend toward improved glycemic control The reduction in glucose exposure occurred overnight and during the day Patient reported data from the device use questionnaire revealed a high level of PaQ satisfaction and acceptance All but one scored above 4 00 indicating high and very high device satisfaction No severe hypoglycemic events occurred during the study baseline period or while participants were on PaQ About PaQ PaQ Insulin Delivery Device is a simple and affordable device that enables patients to experience the benefits of CSII without the burden of daily insulin injections PaQ provides three days of consistent basal insulin along with easy on demand bolus insulin PaQ can reduce known barriers to insulin therapy and has proven effective in clinical trials and usability studies PaQ has CE Mark approval and will address the emerging 3 billion market for simple insulin infusion About CeQur SA CeQur is dedicated to developing and commercializing advanced insulin delivery devices that make it easier for people living with type 2 diabetes to adhere to therapy and stay in control of their disease The company is headquartered in Horw Switzerland with operations in Nordborg Denmark and Marlborough Massachusetts CeQur was established in January 2008 The company s lead product candidate is the PaQ Insulin Delivery Device a novel wearable device that provides freedom from multiple daily injections More information can be found at www cequrcorp com 1 Hoerger T et al Is Glycemic Control Improving in U S Adults Diabetes Care 2008 31 81 86 2 Peyrot M Rubin RR Kruger DF Travis LB Correlates of insulin injection omission Diabetes Care 2010 33 240 5 Contact Michele Parisi for CeQur 1 925 429 1850 mparisi biocommnetwork com back Endeavour Vision SA 2006 2016 Terms Conditions The partners have been very supportive of our approach and stepped in to add value when needed I would strongly recommend them as investors Didier Cowling Founder and CEO Kuros Biosurgery AG In preparing for our dual IPOs on the Nasdaq and Neuer Markt it was very important for SCM Microsystems to gain insight

    Original URL path: http://www.endeavourvision.com/news-n216-c67-Diabetes+Care+Publishes+Data+Demonstrati.htm (2016-04-25)
    Open archived version from archive

  • CeQur to Present at the 32nd Annual J.P. Morgan Healthcare Conference
    insulin along with easy on demand bolus insulin PaQ can reduce known barriers to insulin therapy and has proven effective in clinical trials and usability studies PaQ has CE Mark approval and will address the emerging 3 billion market for simple insulin infusion About CeQur CeQur is developing and commercializing advanced insulin delivery devices that make it easier for people living with type 2 diabetes to adhere to therapy and stay in control of their disease CeQur was established in 2008 and is headquartered in Horw Switzerland with operations in Nordborg Denmark and Marlborough Massachusetts More information about CeQur and PaQ can be found at www cequrcorp com Contact Michele Parisi for CeQur 1 925 429 1850 mparisi biocommnetwork com back Endeavour Vision SA 2006 2016 Terms Conditions The partners have been very supportive of our approach and stepped in to add value when needed I would strongly recommend them as investors Didier Cowling Founder and CEO Kuros Biosurgery AG In preparing for our dual IPOs on the Nasdaq and Neuer Markt it was very important for SCM Microsystems to gain insight and access to the European investment scene This team helped SCM build the foundation for our successful offerings not only with capital but with sound guidance and value added services as well Robert Schneider founder and CEO SCM Microsystems Inc VC is about funding your project but it is more about extending your core team Thus it is about partnering with those who are great to work with and are team players Those who understand your business and embrace your vision Those who know how to challenge your execution and to bring value This is why I recommend Endeavour Vision team to entrepreneurs looking for funding Dr Georges Karam co Founder President CEO Sequans With Endeavour Vision we

    Original URL path: http://www.endeavourvision.com/news-n211-c67-CeQur+to+Present+at+the+32nd+Annual+J.P..htm (2016-04-25)
    Open archived version from archive

  • Data Demonstrating Potential Benefits of Simple Insulin Delivery Device Presented at European Association for the Study of Diabetes Annual Meeting
    values during PaQ therapy showed a trend toward better glycemic control compared to baseline at multiple points throughout the day Blinded continuous glucose monitoring CGM data during PaQ therapy also revealed a trend toward improved glycemic control The reduction in glucose exposure occurred overnight and during the day and CGM revealed no episodes of severe hypoglycemia Previous studies have demonstrated that CSII may improve treatment satisfaction among people with type 2 diabetes and may thereby improve glycemic control or willingness to switch to insulin said John Pickup MD professor of Diabetes and Metabolism at the Kings College London School of Medicine But we need devices that are less complex and more affordable Simpler insulin delivery devices such as the PaQ are both clinically and economically justified for type 2 diabetes Previously presented data from the Graz study demonstrate that PaQ safely and effectively delivered patients insulin requirements No severe hypoglycemic events occurred during the study baseline period or while participants were on PaQ and all patients were able to correctly assemble and use PaQ with just one hour of training CeQur recently announced the closing of a 27 million dollar Series B financing that will support manufacturing scale up for PaQ which received CE Mark approval in November 2012 and fund activities related to United States regulatory approval The Need for Simple Insulin Infusion There are currently more than 11 million people in the United States and European Union who are taking insulin injections to manage their T2D Studies suggest that simple CSII regimens may improve glycemic control and quality of life among these individuals However current CSII has not been widely used in T2D to date due to its complexity and cost About PaQ PaQ is a discreet wearable device that provides three days of consistent basal insulin delivery along with easy on demand bolus insulin The small device comprises a disposable insulin infuser reservoir attached to a reusable insulin monitor About CeQur SA CeQur is dedicated to developing and commercializing advanced insulin delivery devices that make it easier for people living with type 2 diabetes to adhere to therapy and stay in control of their disease The company is headquartered in Horw Switzerland with operations in Nordborg Denmark and Marlborough Massachusetts CeQur was established in January 2008 The company s lead product candidate is the PaQ Insulin Delivery Device a novel wearable device that provides freedom from multiple daily injections More information can be found at www cequrcorp com 1 Hoerger T et al Is Glycemic Control Improving in U S Adults Diabetes Care 2008 31 81 86 2 Peyrot M Rubin RR Kruger DF Travis LB Correlates of insulin injection omission Diabetes Care 2010 33 240 5 back Endeavour Vision SA 2006 2016 Terms Conditions The partners have been very supportive of our approach and stepped in to add value when needed I would strongly recommend them as investors Didier Cowling Founder and CEO Kuros Biosurgery AG In preparing for our dual IPOs on the Nasdaq and

    Original URL path: http://www.endeavourvision.com/news-n201-c67-Data+Demonstrating+Potential+Benefits+of.htm (2016-04-25)
    Open archived version from archive

  • CeQur SA Closes $27 Million Series B Financing
    need PaQ is a discreet wearable device that provides three days of consistent basal insulin delivery along with easy on demand bolus insulin The small device comprises a disposable insulin infuser reservoir attached to a reusable insulin monitor PaQ is simple to use making it easy to train patients to start and stay on therapy Working with one of the most qualified management teams in diabetes the new investors will support the commercialization phase and set up of high volume manufacturing for PaQ said Damien Tappy president and managing partner of Endeavour Vision Given the track record of this management team we are confident that this funding will enable both the evolution of CeQur into a company that helps redefine the type 2 diabetes landscape and the launch of PaQ into what is a 3 billion addressable market The Need for Simple Insulin Infusion There are currently more than 11 million people in the United States and European Union who are taking insulin injections to manage their type 2 diabetes T2D Studies suggest that continuous subcutaneous insulin infusion CSII regimens may improve glycemic control and quality of life among these individuals However current CSII has not been widely used in T2D to date due to its complexity and cost We ve developed a simple and affordable insulin delivery solution for people with type 2 diabetes that can free them from the burden of multiple daily injections so that they can more comfortably and consistently maintain target glycemic values said James Peterson founder and CEO CeQur About CeQur SA CeQur is dedicated to developing and commercializing advanced insulin delivery devices that make it easier for people living with type 2 diabetes to adhere to therapy and stay in control of their disease The company is headquartered in Horw Switzerland with operations in Nordborg Denmark and Marlborough Massachusetts CeQur was established in January 2008 The company s lead product candidate is the PaQ Insulin Delivery Device a novel wearable device that provides freedom from multiple daily injections More information can be found at www cequrcorp com Contact Michele Parisi 1 925 429 1850 mparisi biocommnetwork com back Endeavour Vision SA 2006 2016 Terms Conditions The partners have been very supportive of our approach and stepped in to add value when needed I would strongly recommend them as investors Didier Cowling Founder and CEO Kuros Biosurgery AG In preparing for our dual IPOs on the Nasdaq and Neuer Markt it was very important for SCM Microsystems to gain insight and access to the European investment scene This team helped SCM build the foundation for our successful offerings not only with capital but with sound guidance and value added services as well Robert Schneider founder and CEO SCM Microsystems Inc VC is about funding your project but it is more about extending your core team Thus it is about partnering with those who are great to work with and are team players Those who understand your business and embrace your vision Those who know

    Original URL path: http://www.endeavourvision.com/news-n198-c67-CeQur+SA+Closes+%2427+Million+Series+B+F.htm (2016-04-25)
    Open archived version from archive



  •